Evaluating PTSD: The Role of the TSI-2 in Improving Treatment Outcomes for Adults with Posttraumatic Symptoms

Summary: PTSD doesn't look the same in everyone—and new 2026 research is reshaping how clinicians understand it. With roughly 13 million Americans affected each year and most first-line therapies failing the majority of patients, the case for thorough, individualized evaluation has never been stronger. Here's what the latest science reveals about the two faces of PTSD—and why the right assessment tool matters more than ever.

We all experience moments of stress in our lives, but some events leave a lasting mark. Posttraumatic stress disorder (PTSD) is a mental health condition caused by experiencing or witnessing an extremely traumatic event. While it is common to have difficulty coping after trauma, people with PTSD have symptoms—such as flashbacks, nightmares, severe anxiety, or uncontrollable thoughts about the event—that worsen or persist months to years later. June marks PTSD Awareness Month, a time to bring attention to this condition and how to access treatment.

Why It Matters Now

Approximately 6 out of every 100 people (or 6% of the U.S. population) will have PTSD at some point in their lives. The effects are disruptive and potentially destructive, affecting almost every aspect of daily life.

2026 Update—Prevalence

Updated data puts the current number of Americans living with PTSD in any given year at approximately 13 million—up from earlier estimates (VA National Center for PTSD). Fewer than 60% of adults with PTSD receive any form of mental health treatment, underscoring the ongoing gap between need and care (National Alliance on Mental Illness, 2024).

2026 Update—A Broader Clinical Picture

Research published in January 2026 by Yale School of Medicine reveals that PTSD is more complex than previously understood. Studying more than 800 trauma-exposed individuals, researchers identified 2 distinct symptom profiles: a fear-based profile (flashbacks, hypervigilance, nightmares) and an emotional pain profile (loss of interest, negative beliefs, emotional reactivity, trouble sleeping). Notably, nearly 70% of participants rated emotional pain as more impairing than fear. This distinction suggests different underlying neural mechanisms—and may call for different treatment approaches depending on which profile a patient presents.

Understanding the Cause and Symptoms of PTSD

PTSD develops in about one in three people who experience severe trauma. Anyone can develop PTSD after a severely stressful or disturbing event—not only military veterans, though they face a higher likelihood of exposure. Genetic and biological factors, including pre-existing depression or anxiety, can also increase risk. Women are more likely than men to develop PTSD, in part because of the types of trauma women are more likely to experience.

Symptoms typically appear within the first 3 months following trauma, though they can emerge years later. They fall into 4 categories: intrusive memories, avoidance, negative changes in thinking and mood, and changes in physical and emotional reactivity. If symptoms persist for more than a month, seeking help from a healthcare provider or mental health professional is important. Untreated, PTSD can worsen over time and significantly impair daily functioning.

The Importance of Evaluating PTSD

Because of the complexity of PTSD—and the reality that standard first-line therapies do not work for everyone—thorough assessment is essential for determining the best possible treatment. The assessment process includes a short screening followed by a more in-depth evaluation of the patient's thoughts, feelings, and behaviors since the trauma.

2026 Update—Treatment Gaps

Research confirms that between 60% and 72% of military and veteran populations do not experience meaningful relief from first-line therapies such as Cognitive Processing Therapy, Prolonged Exposure, and EMDR (Steenkamp, Litz, Hoge, & Marmar, JAMA, 2015). For civilians, non-response rates are approximately 39% (Semmlinger et al., Depression and Anxiety, 2024). These numbers reinforce why comprehensive, individualized assessment matters—a single treatment path does not fit all presentations. The 2026 Yale findings further support this: identifying whether a patient's dominant profile is fear-based or emotional-pain-based could help clinicians select interventions more precisely and improve outcomes.

Why the TSI-2?

This is where tools like the Trauma Symptom Inventory™-2 (TSI™-2) make a measurable difference. With an administration time of just 20 minutes, the TSI-2 is a broadband measure that evaluates acute and chronic posttraumatic symptomatology. It is a self-report instrument designed with a variety of features, including:

• Three scales (Insecure Attachment, Somatic Preoccupations, and Suicidality) and several subscales, as well as four summary factors (Self-Disturbance, Posttraumatic Stress, Externalization, and Somatization).
• Items that assess clients' tendencies to deny symptoms, over-endorse unusual symptoms, or respond randomly; the instrument addresses malingering.
• A standardization sample (N = 678) that closely matches U.S. Census statistics.
• Easy administration and scoring, including online options available on PARiConnect.
• TSI-2 Alternative Form (TSI-2-A) and Spanish versions available.

The breadth of what the TSI-2 captures—across fear-based and emotional pain dimensions alike—positions it well to support the kind of nuanced clinical picture the latest research calls for.

The Takeaway

PTSD is not one condition with one presentation. The science increasingly shows that effective care depends on understanding which symptoms are driving impairment for each individual patient. Thorough evaluation is the foundation of that understanding—and it must come before any treatment decision is made.

As we continue to raise awareness about PTSD this month, consider whether your current evaluation process gives you the full picture your patients need. The TSI-2 was built for exactly that purpose.